Lutzker Stuart 4

What Happened
Stuart Lutzker, President of R&D and a director at ArriVent BioPharma (AVBP), was granted a derivative award covering 150,000 shares on February 2, 2026. The Form 4 reports an acquisition price of $0.00 for the award (no cash paid at grant); the filing classifies this as a derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04. No late filing indicated in the Form 4.
• Transaction type: Grant/Award (derivative securities) — 150,000 shares reported at $0.00.
• Vesting: 25% vests on February 2, 2027, then the remainder vests in 36 equal monthly installments thereafter (subject to continued service).
• Shares owned after the transaction: not disclosed in this filing.
• No immediate sale or cashless exercise reported; this is a time-vesting compensation award.

Context
This grant appears to be a compensation-related derivative award (e.g., RSUs or an option-style award) that vests over time and depends on Lutzker’s continued service. Such grants are routine executive compensation and do not represent an open-market purchase or sale by the insider. Retail investors should note the vesting schedule — future ownership and potential selling activity will depend on vesting and whether the insider later exercises or sells any vested shares.